Imagion Biosystems has today advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO, Bob Proulx today, Thursday 10 September, under the terms of Mr Proulx’s employment agreement.
The attached ASX announcements in relation to issue of shares to Mr Proulx as a result of vesting of performance rights were released to market.
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session
Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, announces it has initiated plans to separate the
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
